Introduction: Treatment for rectal cancer results in sexual dysfunction. Sexual function is a component of the HR-QOL (health related quality of life) measures. The incidence of sexual dysfunction following treatment for rectal cancer and its impact on the HR-QOL is not well delineated, particularly on women.
Objectives: To prospectively assess the degree of sexual dysfunction that occurs after treatment for Stage I-III rectal cancer and the corresponding short term (<3 months) and long term (<2 years) effect on the Quality of Life measure for oncology (QOL-30).
Methods: Validated questionnaires will be administered to assess sexual function and quality of life. The International Index of Erectile Dysfunction will be administered to male patients and the Female Sexual Function Index to female patients. The European Organization for Research and Treatment of Cancer Quality of Life measure for oncology (EORTC QOL-30) and Quality of Life Questionnaire Colorectal Cancer Module (QOL-29) will be administered to assess quality of life. Survey’s will be administered at the time of diagnosis of rectal cancer and repeat the instrument 3 months and 2 years after completion of therapy.
Results: The author identified relevant background literature from three databases: PubMed, Web of Science, and PsycInfo. The author accessed these databases via the University of New Mexico Health Sciences Library and Informatics Center and added to a citation manager.
Conclusion: There is growing interest in cancer survivorship and sexual function based on the current literature, but few prospective trials evaluating sexual function in rectal cancer patients.
Rectal neoplasms; Sexual dysfunction, physiological; Quality of life; Bibliographic databases; Health Related Quality Of Life (HR-QOL); Medical informatics; Low anterior
Popek, Sarah M.. "Sexual Dysfunction after Rectal Cancer Treatment." (2020). https://digitalrepository.unm.edu/hsc_ctsc_trainee_papers/21